Menu
Log in
Forgot password
Log in
Forgot password

News

  • Home
  • Resources
  • Literature Updates
  • Etrasimod as a treatment for eosinophilic oesophagitis (VOYAGE): a double-blind, placebo-controlled, randomised, phase 2 trial

Etrasimod as a treatment for eosinophilic oesophagitis (VOYAGE): a double-blind, placebo-controlled, randomised, phase 2 trial

26 Jun 2025 12:59 PM | Anonymous member (Administrator)

Evan S Dellon; Margaret H Collins; Albert J Bredenoord; Hamish Philpott; Luc Biedermann; Márjori Dulcine; Thai Nguyen-Cleary; Chinyu Su; Jin Yu; Huaming Tan; Fabio Cataldi; Joseph Wu; Wenjin Wang; Pamela Clax; John C Woolcott;  Ikuo Hirano

Read Abstract: Etrasimod as a treatment for eosinophilic oesophagitis (VOYAGE): a double-blind, placebo-controlled, randomised, phase 2 trial

Affiliated Societies



International  Interdisciplinary  Everything Esophageal


The International Society for Diseases of the Esophagus is a 501(c)3 non-profit organization. © International Society for Disease of the Esophagus – ISDE 2024 | Any unauthorized use or reproduction of the content is prohibited without explicit permission.

General Inquiries: info@isde.net
Membership Questions: membership@isde.net

Powered by Wild Apricot Membership Software